Your browser doesn't support javascript.
loading
In Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen.
Amirrajab, Nasrin; Badali, Hamid; Didehdar, Mojtaba; Afsarian, Mohammad Hosein; Mohammadi, Rasoul; Lotfi, Nazanin; Shokohi, Tahereh.
Afiliación
  • Amirrajab N; Department of Laboratory Sciences, School of Paramedicine and Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran; Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran.
  • Badali H; Department of Medical Mycology and Parasitology, Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran.
  • Didehdar M; Department of Medical Mycology and Parasitology, Faculty of Medicine, Arak University of Medical Sciences, Arak, IR Iran.
  • Afsarian MH; Department of Microbiology, Fasa University of Medical Sciences, Fasa, IR Iran.
  • Mohammadi R; Department of Medical Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IR Iran.
  • Lotfi N; Department of Medical Mycology and Parasitology, Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran.
  • Shokohi T; Department of Medical Mycology and Parasitology, Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran.
Jundishapur J Microbiol ; 9(5): e36638, 2016 May.
Article en En | MEDLINE | ID: mdl-27540459
BACKGROUND: Candida glabrata is a pathogenic yeast with several unique biological features and associated with an increased incidence rate of candidiasis. It exhibits a great degree of variation in its pathogenicity and antifungal susceptibility. OBJECTIVES: The aim of the present study was to evaluate the in vitro antifungal susceptibilities of the following six antifungal drugs against clinical C. glabrata strains: amphotericin B (AmB), ketoconazole (KTZ), fluconazole (FCZ), itraconazole (ITZ), voriconazole (VCZ), and caspofungin (CASP). MATERIALS AND METHODS: Forty clinical C. glabrata strains were investigated using DNA sequencing. The in vitro antifungal susceptibility was determined as described in clinical laboratory standard institute (CLSI) documents (M27-A3 and M27-S4). RESULTS: The sequence analysis of the isolate confirmed as C. glabrata and deposited on NCBI GenBank under the accession number no. KT763084-KT763123. The geometric mean MICs against all the tested strains were as follows, in increasing order: CASP (0.17 g/mL), VCZ (0.67 g/mL), AmB (1.1 g/mL), ITZ (1.82 g/mL), KTZ (1.85 g/mL), and FCZ (6.7 g/mL). The resistance rates of the isolates to CASP, FCZ, ITZ, VZ, KTZ, and AmB were 5%, 10%, 72.5%, 37.5%, 47.5%, and 27.5%, respectively. CONCLUSIONS: These findings confirm that CASP, compared to the other antifungals, is the potent agent for treating candidiasis caused by C. glabrata. However, the clinical efficacy of these novel antifungals remains to be determined.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Jundishapur J Microbiol Año: 2016 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Jundishapur J Microbiol Año: 2016 Tipo del documento: Article Pais de publicación: Países Bajos